Literature DB >> 10639648

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art.

.   

Abstract

Platelets have been shown to play an important role in the pathogenesis of atherosclerosis, acute coronary syndromes, and ischemic complications after percutaneous coronary intervention. Fibrinogen binding via platelet surface glycoprotein (GP) IIb/IIIa receptors constitutes the "final pathway" in platelet aggregation leading to thrombus formation. The GP IIb/IIIa receptor inhibitors, a new class of antiplatelet agents that have emerged in recent years, show great promise in reducing complications of coronary angioplasty and acute coronary syndromes. This review will examine the biology of platelet GP IIb/IIIa receptors, the various classes of GP IIb/IIIa receptor antagonists, the results of the latest clinical trials, and their implications in current clinical practice.

Entities:  

Year:  1997        PMID： 10639648     DOI： 10.1023/a:1008809702729

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  36 in total

1.  Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri.

Authors:  R M Scarborough; J W Rose; M A Hsu; D R Phillips; V A Fried; A M Campbell; L Nannizzi; I F Charo
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

Review 2.  Glanzmann's thrombasthenia: the spectrum of clinical disease.

Authors:  J N George; J P Caen; A T Nurden
Journal:  Blood       Date:  1990-04-01       Impact factor: 22.113

3.  The relation of clinical outcome to dissection and thrombus formation during coronary angioplasty. Heparin Registry Investigators.

Authors:  J J Ferguson; E Barasch; J M Wilson; J Strony; M W Wolfe; M J Schweiger; F Leya; R Bonan; J M Isner; G S Roubin
Journal:  J Invasive Cardiol       Date:  1995 Jan-Feb       Impact factor: 2.022

4.  Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.

Authors:  K M Detre; D R Holmes; R Holubkov; M J Cowley; M G Bourassa; D P Faxon; G R Dorros; L G Bentivoglio; K M Kent; R K Myler
Journal:  Circulation       Date:  1990-09       Impact factor: 29.690

5.  Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia.

Authors:  B S Coller
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

6.  Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile.

Authors:  A M Lincoff; J J Popma; S G Ellis; J A Hacker; E J Topol
Journal:  J Am Coll Cardiol       Date:  1992-04       Impact factor: 24.094

7.  Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin.

Authors:  H R Gralnick; S B Williams; B S Coller
Journal:  Blood       Date:  1984-10       Impact factor: 22.113

8.  Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

Authors:  R A Harrington; N S Kleiman; K Kottke-Marchant; A M Lincoff; J E Tcheng; K N Sigmon; D Joseph; G Rios; K Trainor; D Rose
Journal:  Am J Cardiol       Date:  1995-12-15       Impact factor: 2.778

9.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-07       Impact factor: 91.245

10.  Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.

Authors:  F V Aguirre; E J Topol; J J Ferguson; K Anderson; J C Blankenship; R R Heuser; K Sigmon; M Taylor; R Gottlieb; G Hanovich
Journal:  Circulation       Date:  1995-06-15       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.